Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Leibowitz

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Pageof 12